PGG gains exclusive licence to TheraPEG technology for HA treatment
Pro Bono Bio (PBB) and PolyTherics say they have made progress on a haematology alliance project that aims to produce longer-acting versions of blood factor proteins.
Following an agreement between the parties signed in May 2012, the two companies undertook a feasibility programme to evaluate the use of PolyTherics' TheraPEG technology to develop a long-acting PEGylated form of Factor VIII (TheraPEG FVIII) for the treatment of haemophilia A (HA). The conclusion of this programme has led PBB to exercise an option to take an exclusive, global licence to use TheraPEG technology to develop and commercialise a TheraPEG-FVIII product that will be longer acting than the FVIII products currently in use. Haemophilia patients treated with FVIII prophylactically require treatment on average three times a week. A longer-acting FVIII will therefore enable less frequent dosing of the product and thus greater convenience for patients, particularly those using FVIII for regular prophylaxis against bleeding episodes.